

Supporting Information for

**Psidguajones A and B, a pair of complex meroterpenoid epimers from the leaves of
*Psidium guajava***

*Qing Liu,^a Zhichao Wang,^b Jianming He,^c and Zhenling Liu^{*d}*

^a College of Chemical Engineering, Huaqiao University, Xiamen 361021, China. E-mail:
liuq@hqu.edu.cn

^b College of Chemical Engineering, Northwest Minzu University, Lanzhou, 730030, China.
E-mail: *wangzc@xbmu.edu.cn*

^c School of Pharmacy, Fudan University, Shanghai, 201203, China. E-mail:
13111030015@fudan.edu.cn

^d State Key Laboratory of Applied Organic Chemistry, Lanzhou University, Lanzhou
730000, China. E-mail: *liuzhl@lzu.edu.cn*.

*Corresponding author. E-mail: *liuzhl@lzu.edu.cn*;
Fax/Tel: +86-9318912500

Contents of Supporting Information

Experimental Section

1	S1. Experimental Section	S4
2	Scheme S1. A putative biosynthetic pathway for psidguaiones A and B	S9
 For psidguaione A		
3	Figure S4. HRESIMS of psidguaione A	S10
4	Figure S5. ^1H NMR spectrum of psidguaione A in CDCl_3 500 MHz)	S11
5	Figure S6. ^1H NMR spectrum (δ_{H} 0.6–3.2 ppm) of psidguaione A in CDCl_3 (500 MHz)	S12
6	Figure S7. ^1H NMR spectrum (δ_{H} 5.0–13.5 ppm) of psidguaione A in CDCl_3 (500 MHz)	S13
7	Figure S8. APT spectrum of psidguaione A in CDCl_3 (125 MHz)	S14
8	Figure S9. APT NMR spectrum (δ_{C} 20–40 ppm) of psidguaione A in CDCl_3 (125MHz)	S15
9	Figure S10. ^1H - ^1H COSY spectrum of psidguaione A in CDCl_3	S16
10	Figure S11. ^1H - ^1H COSY spectrum (δ_{H} 0–2.5 ppm) of psidguaione A in CDCl_3	S17
11	Figure S12. TOCSY spectrum of psidguaione A in CDCl_3	S18
12	Figure S13. HSQC spectrum of psidguaione A in CDCl_3	S19
13	Figure S14. HSQC spectrum (δ_{H} 0–3.5 ppm, δ_{C} 0–65 ppm) of psidguaione A in CDCl_3	S20
14	Figure S15. HMBC spectrum of psidguaione A in CDCl_3	S21
15	Figure S16. HMBC spectrum (δ_{H} 0–1.0 ppm, δ_{C} 0–55 ppm) of psidguaione A in CDCl_3	S22
16	Figure S17. HMBC spectrum (δ_{H} 1.1–3.2 ppm, δ_{C} 5–200 ppm) of psidguaione A in CDCl_3	S23
17	Figure S18. HMBC spectrum (δ_{H} 5.2–7.8 ppm, δ_{C} 20–200 ppm) of psidguaione A in CDCl_3	S24
18	Figure S19. HMBC spectrum (δ_{H} 8.2–13.6 ppm, δ_{C} 30–200 ppm) of psidguaione A in CDCl_3	S25
19	Figure S20. NOE spectrum of psidguaione A in CDCl_3	S26
20	Figure S21. NOE spectrum (δ_{H} 0.6–6.8 ppm) of psidguaione A in CDCl_3	S27
21	Figure S22. ROESY spectrum (δ_{H} 0.6–7.6 ppm) of psidguaione A in CDCl_3	S28
22	Figure S23. IR spectrum of psidguaione A	S29

For psidguaione B

23	Figure S24. HRESIMS of psidguaione B	S30
24	Figure S25. ^1H NMR spectrum of psidguaione B in CDCl_3 (500 MHz)	S31
25	Figure S26. ^1H NMR spectrum (δ_{H} 0.6–3.2 ppm) of psidguaione B in CDCl_3 (500 MHz)	S32
26	Figure S27. ^1H NMR spectrum (δ_{H} 4.75–13.0 ppm) of psidguaione B in CDCl_3 (500 MHz)	S33
27	Figure S28. APT spectrum of psidguaione B in CDCl_3 (125 MHz)	S34
28	Figure S29. APT NMR spectrum (δ_{C} 20–38 ppm) of psidguaione B in CDCl_3 (125 MHz)	S35
29	Figure S30. ^1H - ^1H COSY spectrum of psidguaione B in CDCl_3	S36
30	Figure S31. ^1H - ^1H COSY spectrum (δ_{H} 0–3.0 ppm) of psidguaione B in CDCl_3	S37
31	Figure S32. TOCSY spectrum of psidguaione B in CDCl_3	S38
32	Figure S33. HSQC spectrum of psidguaione B in CDCl_3	S39
33	Figure S34. HSQC spectrum (δ_{H} 0–3.2 ppm, δ_{C} 0–55 ppm) of psidguaione B in CDCl_3	S40
34	Figure S35. HMBC spectrum of psidguaione B in CDCl_3	S41
35	Figure S36. HMBC spectrum (δ_{H} 0.6–1.0 ppm, δ_{C} 20–55 ppm) of psidguaione B in CDCl_3	S42
36	Figure S37. HMBC spectrum (δ_{H} 1.1–3.2 ppm, δ_{C} 5–200 ppm) of psidguaione B in CDCl_3	S43
37	Figure S38. HMBC spectrum (δ_{H} 4.7–8.0 ppm, δ_{C} 20–200 ppm) of psidguaione B in CDCl_3	S44
38	Figure S39. HMBC spectrum (δ_{H} 9.5–13.1 ppm, δ_{C} 30–200 ppm) of psidguaione B in CDCl_3	S45
39	Figure S40. NOE spectrum of psidguaione B in CDCl_3	S46
40	Figure S41. NOE spectrum (δ_{H} 0.6–3.2 ppm) of psidguaione B in CDCl_3	S47
41	Figure S42. ROESY spectrum (δ_{H} 0.5–3.2 ppm) of psidguaione B in CDCl_3	S48
42	Figure S43. IR spectrum of psidguaione B	S49
43	Figure S44. UV (CH_2Cl_2) spectra of psidguaiones A and B	S50

S1. Experimental Section

General experimental procedures

Optical rotations were obtained on a Perkin-Elmer 341 polarimeter. IR spectra were determined on a Nicolet NEXUS 670 FT-IR spectrometer. The UV spectra were recorded using a Shimadzu UV-260 spectrophotometer. CD spectra were performed using an Olis DSM 1000 spectropolarimeter and the CD measurements of psidguajones A and B were recorded in dichloromethane at RT (cell length: 0.2 cm) with the concentrations (mg/mL) of 1.10, and 0.74, respectively. 1D and 2D NMR spectra were acquired with Bruker Avance-500 spectrometer (Rheinstetten, Germany) and Bruker Avance III-400 using solvent signal (CDCl_3 : δ_{H} 7.26/ δ_{C} 77.7) as references. The HMQC and HMBC experiments were optimized for 145.0 and 8.0 Hz, respectively. Silica gel 200–300 mesh for column chromatography and silica GF254 (10–40 m) for TLC were supplied by the Qingdao Marine Chemical Inc., China. C18 reversed-phase (RP-18) silica gel (150–200 mesh, Merck, Germany), MCI gel (CHP20P, 75–150 μm , Mitsubishi Chemical Industries Ltd., Japan), and Sephadex LH-20 gel (Merck, Germany) were used for column chromatography. Semipreparative HPLC were performed on a Waters 1525 series instrument equipped with a SunFreTM Prep C18 ODS-A column (150 $\times$ 10 mm, 10 μm , flow rate: 1 mL/min). Solvents used for general chromatography were of analytical grade (Tianjin Chemical Reagents Co. Ltd., China) except that the solvents used for HPLC were of HPLC grade (Thermo Fisher Scientific Inc., China). Cell culture reagents were purchased from Sigma (St Louis, MO, USA), Human lung cancer A549, Human hepatic carcinoma HepG2, Human cervical cancer HeLa, Human breast cancer MCF-7, human colorectal carcinoma HCT-116 cells were obtained from the Shanghai Institute of Biochemistry and Cell Biology (Shanghai, China).

Plant material

The leaves of *Psidium guajava* L. were collected in November of 2012 on the Xiamen Botanical Garden, P. R. China, and were identified by Prof. Z-G Ma, A voucher specimen (no. 20121115) has been deposited at Natural Organic Academy of State Key Laboratory of Lanzhou University

Extraction and isolation

The air-dried leaves of *Psidium guajava* L. (8 kg) were extracted with MeOH (50 L) four times (five days each time) at room temperature and the combined solvent was evaporated under reduced pressure to yield a residue (1106 g). The residue was dissolved in water and extracted with petroleum ether. The petroleum ether fraction (340 g) was dissolved in chloroform and mixed with silica gel (300 g). Then the dry mixture was separated on a column of silica gel (1580 g) eluted with petroleum ether-ethylene acetate (1:0, 19:1, 9:1, 4:1, 2:1, 1:1, 0:1 v:v) to produce seven fractions A-G. The fraction C (12 g) was chromatographed on a silica gel column with petroleum ether-dichloromethane (1:0 to 0:1) as eluent to give six fractions (C1-C6). Fraction C2 (2.0 g) was separated on a column of MCI gel eluted with EtOH-H₂O (5:5, 8:2, 10:0 v:v) to produce four fractions A-C. Fraction C (0.8 g) was passed through a column of Sephadex

LH-20 and further purified on reversed-phase semipreparative HPLC by eluting with acetonitrile-H₂O-formic acid (99:1:0.01, 1mL/min) to afford psidguaione A (4.0 mg) and psidguaione B (4.0 mg).

Psidguaione A: yellow amorphous powder, $[\alpha]_D^{20} = 79$ (c 1.1 in CH₂Cl₂); IR (KBr) $\nu_{\max}$ 3350, 2924, 1765, 1736, 1625, 1561, 1545, 1459, 1382, 1292, 1261, 1120, 1078 cm⁻¹; UV (CH₂Cl₂): $\lambda_{\max}$ (log ϵ) = 231 (4.25), 302 (4.15), 341 (3.74) nm; ¹H and ¹³C NMR data (**Table 1**) in the manuscript; positive HREIMS m/z 931.5146 [M+H]⁺ calcd for 931.5143 [M+H]⁺.

Psidguaione B: yellow amorphous powder, $[\alpha]_D^{20} = -101$ (c 0.7 in CH₂Cl₂); IR (KBr) $\nu_{\max}$ 3319, 2926, 1720, 1628, 1561, 1545, 1443, 1379, 1293, 1263, 1125, 1078 cm⁻¹; UV (CH₂Cl₂): $\lambda_{\max}$ (log ϵ) = 228 (3.99), 299 (3.86), 343 (3.75) nm; ¹H and ¹³C NMR data (**Table 1**) in the manuscript; positive HREIMS m/z 931.5139 [M+H]⁺ calcd for 931.5143 [M+H]⁺.




Figure S1. The structure of psidguaione B

The structural confirmation of psidguaione B

Psidguaione B was obtained as a yellow amorphous powder with a $[\alpha]_D^{20} = -101$ (c 0.7 in CH₂Cl₂). It was assigned to be a stereoisomer of psidguaione A since it had the same molecular formula of C₆₁H₇₀O₈ established by HR-ESI-MS at m/z 931.5139 [M+H]⁺ (calcd. 931.5143) and its NMR spectrum data were nearly the same as those of psidguaione A. Detailed comparison of 1D TOCSY and 2D NMR spectra, especially HMBC (**Fig. 2** in text) data of psidguaione B with those of psidguaione A supported that psidguaione B has an identical planar structure to psidguaione A. Additionally, the relative stereochemistry of the triangle-shaped fragment formed with **1a/1b/1c** of psidguaione B (shown in **Figure 1S**) was fixed and the C-9'' was an individual

chiral carbon based on the fact that the ROESY data and NOE experiment of psidguaione B were highly similar to those of psidguaione A. So just like psidguaione A, there were four configurational isomers of psidguaione B coded as **I-IV**. Then, the CD analysis of psidguaione B indicated that psidguaione B was 9''-*epi*-psidguaione A.

Computational Methods¹

Conformation search for **I-IV** (**Figure S2**) was performed by Spartan's 14 using Merck Molecular Force Field (MMFF) level. The conformers with Boltzmann-population of over 5% were chosen for ECD calculations. The low energy conformations of **I-IV** were submitted to the density functional theory (DFT) optimization at the level of b3lyp/6-31g, using the pcm solvation model with the dielectric constant representing Dichloromethane. The optimized structures were subject to the frequency calculations at b3lyp/6-31g level to confirm the true energy minimal located and generate the thermodynamic data. The optimized structure were further submitted to the Time-dependent density functional theory (TDDFT) calculations at b3lyp/6-31g. Rotatory strengths for a total 100 excited states were calculated and then Boltzmann averaged based on the calculated Gibbs free energy. ECD spectra were generated using the SpecDis 1.70 and GraphPad Prism 5 from dipole-length rotational strengths by applying Gaussian band shapes with 0.16 ev or 0.3 ev. Calculated and experimental CD spectra of psidguaiones A and B were shown in **Figure S3**.





Figure S2. Four configurational isomers of psidguaiones A/B coded as **I-IV**

Table S1. Boltzmann population of the conformer of I, II, III, and IV.

Conformer	Boltzmann distribution (%)	Conformer	Boltzmann distribution (%)	Conformer	Boltzmann distribution (%)	Conformer	Boltzmann distribution (%)
I-1	18.98	II-1	25	III-1	3.13	IV-1	25
I-2	18.98	II-2	25	III-2	3.13	IV-2	25
I-3	15.51	II-3	25	III-3	93.74	IV-3	25
I-4	15.51	II-4	25			IV-4	25
I-5	15.51						

Psidguaajone A



Psidguaajone B




Figure S3. Calculated and experimental CD spectra of psidguaajones A and B

The atom coordinates of one structure of psidguajone A is provided in the independent attachment and the file name was 'Psidguajone A.cif'. The atom coordinates of one structure of Psidguajone B is provided in the independent attachment and the file name was 'Psidguajone B.cif'.

Cell proliferation and cell viability assay²

All cells were cultured in DMEM medium, with 10% fetal Bovine serum (FBS), 2 mM L-glutamine, and 100 µg/mL penicillin and 100 µg/mL streptomycin. The viability of cancer cells was evaluated by MTT assay. Briefly, the cells were inoculated at a density of 5×10^3 . When the cells reached 60% confluence, they were treated with psidguajones A and B in various concentrations for 48 h. Then, MTT (5 mg/mL) was added to cell suspension for 4 h. After the insoluble formazan product was dissolved in dimethyl sulfoxide (DMSO). Optical density (OD) of each culture well was measured using a microplate reader (Thermo Scientific Multiskan GO, Finland) at 570 nm. The viability was calculated by the following formula: (Cell viability) % = $(A_{\text{sample}} - A_{\text{blank}}) / (A_{\text{control}} - A_{\text{blank}}) \times 100$.

Reference

- [1] Gaussian 09, Revision A.01, M. J. Frisch, G. W. Trucks, H. B. Schlegel, G. E. Scuseria, M. A. Robb, J. R. Cheeseman, G. Scalmani, V. Barone, B. Mennucci, G. A. Petersson, H. Nakatsuji, M. Caricato, X. Li, H. P. Hratchian, A. F. Izmaylov, J. Bloino, G. Zheng, J. L. Sonnenberg, M. Hada, M. Ehara, K. Toyota, R. Fukuda, J. Hasegawa, M. Ishida, T. Nakajima, Y. Honda, O. Kitao, H. Nakai, T. Vreven, J. A. Montgomery, Jr., J. E. Peralta, F. Ogliaro, M. Bearpark, J. J. Heyd, E. Brothers, K. N. Kudin, V. N. Staroverov, R. Kobayashi, J. Normand, K. Raghavachari, A. Rendell, J. C. Burant, S. S. Iyengar, J. Tomasi, M. Cossi, N. Rega, J. M. Millam, M. Klene, J. E. Knox, J. B. Cross, V. Bakken, C. Adamo, J. Jaramillo, R. Gomperts, R. E. Stratmann, O. Yazyev, A. J. Austin, R. Cammi, C. Pomelli, J. W. Ochterski, R. L. Martin, K. Morokuma, V. G. Zakrzewski, G. A. Voth, P. Salvador, J. J. Dannenberg, S. Dapprich, A. D. Daniels, O. Farkas, J. B. Foresman, J. V. Ortiz, J. Cioslowski, and D. J. Fox, Gaussian, Inc., Wallingford CT, 2009.
- [2] Zhang Junmin, Li Ya, Duan Dongzhu, Yao Juan, Gao Kun, Fang Jianguo. Inhibition of thioredoxin reductase by alantolactone prompts oxidative stress-mediated apoptosis of HeLa cells. *Biochemical Pharmacology* <http://dx.doi.org/10.1016/j.bcp.2015.12.004>

Scheme S1. A putative biosynthetic pathway for psidguaiones A and B.




Figure S4. HRESIMS of psidguaione A




Figure S5. ^1H NMR spectrum of psidguaione A in CDCl_3 (500 MHz)




Figure S6. ^1H NMR spectrum (δ_{H} 0.6–3.2 ppm) of psidguaione A in CDCl_3 (500 MHz)




Figure S7. ^1H NMR spectrum (δ_{H} 5.0–13.5 ppm) of psidguaione A in CDCl_3 (500 MHz)




Figure S8. APT spectrum of psidguaione A in CDCl₃ (120 MHz)




Figure S9. APT NMR spectrum (δ_c 20–40 ppm) of psidguaione A in $CDCl_3$ (120MHz)




Figure S10. ^1H - ^1H COSY spectrum of psidguaajone A in CDCl_3





Figure S11. ^1H - ^1H COSY spectrum (δ_{H} 0–2.5 ppm) of psidguaione A in CDCl_3




Figure S12. TOCSY spectrum of psidguajone A in CDCl₃




Figure S13. HSQC spectrum of psidguaione A in CDCl₃




Figure S14. HSQC spectrum (δ_{H} 0–3.5 ppm, δ_{C} 0–65 ppm) of psidguaione A in CDCl_3




Figure S15. HMBC spectrum of psidguaione A in CDCl₃




Figure S16. HMBC spectrum (δ_{H} 0–1.0 ppm, δ_{C} 0–55 ppm) of psidguaione A in CDCl_3




Figure S17. HMBC spectrum (δ_{H} 1.1–3.2 ppm, δ_{C} 5–200 ppm) of psidguaajone A in CDCl_3




Figure S18. HMBC spectrum (δ_{H} 5.2–7.8 ppm, δ_{C} 20–200 ppm) of psidguaione A in CDCl_3




Figure S19. HMBC spectrum (δ_{H} 8.2–13.6 ppm, δ_{C} 30–200 ppm) of psidguaione A in CDCl_3




Figure S20. NOE spectrum of psidguaione A in CDCl₃




Figure S21. NOE spectrum (δ_{H} 0.6–6.8 ppm) of psidguaione A in CDCl_3




Figure S22. ROESY spectrum (δ_{H} 0.6–7.6 ppm) of psidguaione A in CDCl_3





Figure S23. IR spectrum of psidguajone A




Figure S24. HRESIMS of psidguajone B




Figure S25. ^1H NMR spectrum of psidguaione B in CDCl_3 (500 MHz)




Figure S26. ^1H NMR spectrum (δ_{H} 0.6–3.2 ppm) of psidguaione B in CDCl_3 (500 MHz)




Figure S27. ^1H NMR spectrum (δ_{H} 4.75–13.0 ppm) of psidguaione B in CDCl_3 (500 MHz)




Figure S28. APT spectrum of psidguajone B in CDCl₃ (120 MHz)




Figure S29. APT NMR spectrum (δ_c 20–38 ppm) of psidguajone B in CDCl_3 (120MHz)




Figure S30. ^1H - ^1H COSY spectrum of psidguaajone B in CDCl_3






Figure S31. ^1H - ^1H COSY spectrum (δ_{H} 0–3.0 ppm) of psidguaione B in CDCl_3






Figure S33. HSQC spectrum of psidguaione B in CDCl₃





Figure S34. HSQC spectrum (δ_{H} 0–3.2 ppm, δ_{C} 0–55 ppm) of psidguaione B in CDCl_3





Figure S35. HMBC spectrum of psidguaione B in CDCl₃





Figure S36. HMBC spectrum (δ_{H} 0.6–1.0 ppm, δ_{C} 20–55 ppm) of psidguaajone B in CDCl_3




Figure S37. HMBC spectrum (δ_{H} 1.1–3.2 ppm, δ_{C} 5–200 ppm) of psidguaajone B in CDCl_3





Figure S38. HMBC spectrum (δ_{H} 4.7–8.0 ppm, δ_{C} 20–200 ppm) of psidguajone B in CDCl_3





Figure S39. HMBC spectrum (δ_{H} 9.5–13.1 ppm, δ_{C} 30–200 ppm) of psidguaione B in CDCl_3




Figure S40. NOE spectrum of psidguaione B in CDCl₃




Figure S41. NOE spectrum (δ_{H} 0.6–3.2 ppm) of psidguaione B in CDCl_3





Figure S42. ROESY spectrum (δ_{H} 0.5–7.8 ppm) of psidguaione B in CDCl_3





Figure S43. IR spectrum of psidguajone B




Figure S44. UV (CH₂Cl₂) spectra of psidguajones A and B

